Skip to main content
SpringerLink
Log in

New and Established Topical Corticosteroids in Dermatology

Clinical Pharmacology and Therapeutic Use

  • Review Article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Currently, topical glucocorticosteroids are the most frequently used drugs in dermatologic practice. Over the years, research has focused on strategies to optimize potency and, in particular, the anti-inflammatory and immunosuppressive capacity of these drugs, while minimizing adverse effects. However, ‘ideal’ topical corticosteroids have not yet been synthesized. They should be able to permeate the stratum corneum and reach adequate concentrations in the skin without reaching high serum concentrations. Such characteristics can be obtained by increasing the natural lipophilicity of corticosteroids, e.g. by esterification. In the past, many structural modifications have been made to improve the efficacy of topical corticosteroids to produce drugs with greater potency, although this has often been associated with a higher likelihood of adverse effects. Betamethasone dipropionate and clobetasol propionate, known as fifth-generation corticosteroids, are a typical example of potent molecules that can control specific dermatoses very rapidly, but which are associated with a high risk of topical and systemic adverse effects.

Recently, steroid components have been synthesized that aim to have adequate anti-inflammatory effects and minimal adverse effects. The newest topical corticosteroids used for the treatment of different dermatoses and allergic reactions of the respiratory tract (in particular asthma) are budesonide, mometasone furoate, prednicarbate, the di-esters 17,21-hydrocortisone aceponate and hydrocortisone-17-butyrate-21-propionate, methylprednisolone aceponate, alclometasone dipropionate, and carbothioates such as fluticasone propionate. These new topical corticosteroids are evaluated in the current review, which compares the risk/benefit ratio of each molecule with established agents. The new molecules, compared with the well known and established corticosteroids, generally have a higher anti-inflammatory effect, good compliance among patients (only a once-daily application is needed), rarely induce cross-sensitivity reactions and have weak atrophogenicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Table III
Table IV

Similar content being viewed by others

References

  1. Goldman L., Thomson R.G., Trice E.R. Cortisone acetate in skin disease: local effect in skin from topical applicants and local injections. AMA Arch Dermatol Syph 1952; 19: 101–2

    Google Scholar 

  2. Murray J.R. The history of corticosteroids. Acta Derm Venereol 1989; 69 Suppl. 151: 4–6

    Google Scholar 

  3. Ballare P.L., Baxter J.D., Higgins S.J., et al. General presence of glucocorticoid receptors in mammalian tissue. Endocrinology 1974; 94: 998–1002

    Article  Google Scholar 

  4. Epstein E.H., Bonifas J.M. Glucocorticoid receptors of the human epidermis. J Invest Dermatol 1982; 78: 144–6

    Article  PubMed  CAS  Google Scholar 

  5. De Bosscher K., Vanden Berghe W., Haegeman G. Mechanism of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000; 109 (1): 16–22

    Article  PubMed  Google Scholar 

  6. Biola A., Pallardy M. Mode of action of glucocorticoids. Presse Med 2000; 29 (4): 215–23

    PubMed  CAS  Google Scholar 

  7. Blackwell G.J., Carnuccio R., DiRosa M., et al. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticosteroids. Nature 1980; 287: 147–9

    Article  PubMed  CAS  Google Scholar 

  8. Hirata F., Schiffmann E., Venkatasubamanian K., et al. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticosteroids. Proc Natl Acad Sci USA 1980; 77: 2533–6

    Article  PubMed  CAS  Google Scholar 

  9. Kragballe K. Topical corticosteroids: mechanisms of action. Acta Derm Venereol 1989; 69 Suppl. 151: 7–10

    Google Scholar 

  10. Prillo J.E., Fauci A.S. Mechanisms of glucocorticoid action on immune processes. Ann Rev Pharmacol Toxicol 1979; 19: 179–201

    Article  Google Scholar 

  11. Vernon-Roberts B. The effects of steroid hormones on macrophage activity. Int Rev Cytol 1969; 25: 131–59

    Article  PubMed  CAS  Google Scholar 

  12. Thompson J., van Furth R. The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. J Exp Med 1970; 131: 429–42

    Article  PubMed  CAS  Google Scholar 

  13. Newton R. Molecular mechanism of glucocorticoid action: what is important? Thorax 2000; 55: 603–13

    Article  PubMed  CAS  Google Scholar 

  14. Ashwell J.D., Lu F.W., Vacchio M.S. Glucocorticoids in T cell development and function. Annu Rev Immunol 2000; 18: 309–45

    Article  PubMed  CAS  Google Scholar 

  15. Marks R., Williams K. The action of topical corticosteroids on the epidermal cell cycle. In: Wilson J.H., Marks P.A., editors. Mechanisms of topical corticosteroid activity. Edinburgh: Churchill Livingstone, 1976: 39–45

  16. Munro D., Pringle W.M. Psoriasis: its response to dithranol and clobetasol propionate; a comparative study. In: Wilson J.H., Marks P.A., editors. Mechanisms of topical corticosteroid activity. Edinburgh: Churchill Livingstone, 1976: 88–100

    Google Scholar 

  17. Altura B.M. Role of glucocorticosteroids in local regulation of blood flow. Am J Physiol 1966; 211: 1393–7

    PubMed  CAS  Google Scholar 

  18. Juhlin L., Michaelsson G. Cutaneous vascular reactions to prostaglandins in healthy subjects and in patients with urticaria and atopic dermatitis. Acta Derm Venereol 1969; 49: 251–61

    PubMed  CAS  Google Scholar 

  19. Lavker R., Scheckter N. Cutaneous mast cell depletion results from topical corticosteroid usage. J Immunol 1985; 135: 2368–73

    PubMed  CAS  Google Scholar 

  20. Scoggins R.B., Kliman B. Relative potency of percutaneously absorbed corticosteroids in the suppression of pituitary-adrenal function. J Invest Dermatol 1965; 45: 347–55

    PubMed  CAS  Google Scholar 

  21. Ortega E., Burdick K.H., Segre E.J. Adrenal suppression by clobetasol propionate. Lancet 1975; I (7917): 1200

    Article  Google Scholar 

  22. Gomez E.L., Frost P. Induction of glycosuria and hyperglycaemia by topical corticosteroid therapy. Arch Dermatol 1976; 112: 1559–62

    Article  PubMed  CAS  Google Scholar 

  23. Staughton R.C.D., August P.J. Cushing’s syndrome and pituitary-adrenal suppression due to clobetasol propionate. BMJ 1975; 2: 419–21

    Article  PubMed  CAS  Google Scholar 

  24. Fisher D.A. Adverse effects of topical corticosteroid use. West J Med 1995; 162: 123–6

    PubMed  CAS  Google Scholar 

  25. Litt J.Z. Steroid-induced rosacea. Am Fam Phys 1993; 48: 67–71

    CAS  Google Scholar 

  26. Sneddon I.B. Perioral dermatitis. Br J Dermatol 1972; 87: 430–4

    Article  PubMed  CAS  Google Scholar 

  27. Hurwitz R.N. Steroid acne. J Am Acad Dermatol 1989; 21: 1179–81

    Article  PubMed  CAS  Google Scholar 

  28. Rook A., Dawber R. Hypertrichosis. In: Rook A., Dawber R., editors. Diseases of the hair and scalp. London: Blackwell Science, 1982: 256

    Google Scholar 

  29. Renfo L., Snow J.S. Ocular effects and systemic steroids. Dermatol Clin 1992; 10 Suppl. 3: 505–12.

    Google Scholar 

  30. Solomon B.A., Glass A.T., Rabbin P.E. Tinea incognita and over-the-counter potent topical corticosteroids. Cutis 1996; 58 Suppl. 4: 295–6.

    PubMed  CAS  Google Scholar 

  31. Anigbogu A.N., Maibach H.I. Topical corticosteroid therapy. In: Millikan L.E., editor. Drug therapy in dermatology. New York: Marcel Dekker Inc., 2000: 1–29

    Google Scholar 

  32. English J.S. Corticosteroid-induced contact dermatitis: a pragmatic approach. Clin Exp Dermatol 2000; 25 (4): 261–4

    Article  PubMed  CAS  Google Scholar 

  33. Baumann L., Kerdel F. Topical glucocorticosteroids. In: Fitzpatrick T., editor. Dermatology in general medicine. 5th ed. New York: McGraw Hill, 1999: 2713–7

    Google Scholar 

  34. Thomson K.F., Wilkinson S.M., Powell S., et al. The prevalence of corticosteroid allergy in two U.K. centres: prescribing implications. Br J Dermatol 1999; 141: 863–6

    Article  PubMed  CAS  Google Scholar 

  35. Wilkinson S.M., Jones M.F. Corticosteroid usage and binding to arginine: determinants of corticosteroid hypersensitivity. Br J Dermatol 1996; 135: 225–30

    Article  PubMed  CAS  Google Scholar 

  36. Bircher A.J., Bigliardi P., Zaugg T., et al. Delayed generalized allergic reactions to corticosteroids. Dermatology 2000; 200: 349–51

    Article  PubMed  CAS  Google Scholar 

  37. Ohi T. Contact dermatitis due to topical steroids with a conceivable cross-reaction between topical steroid preparations. J Dermatol 1996; 23: 200–8

    CAS  Google Scholar 

  38. McKenna D.B., Murphy G.M. Contact allergy to topical corticosteroids and systemic allergy to prednisolone. Contact Dermatitis 1998; 38: 121–2

    Article  PubMed  CAS  Google Scholar 

  39. Goossens A., Matura M., Degreef H. Reactions to corticosteroids: some new aspects regarding cross-sensitivity. Cutis 2000; 65: 43–5

    PubMed  CAS  Google Scholar 

  40. Coopman S., Degreef H., Dooms-Goossens A. Identification of cross-reaction patterns in allergic contact dermatitis from topical corticosteroids. Br J Dermatol 1989; 121: 27–34

    Article  PubMed  CAS  Google Scholar 

  41. Corazza M., Mantovani L., Maranini C., et al. Contact sensitization to corticosteroids: increased risk in long-term dermatoses. Eur J Dermatol 2000; 10 (7): 533–55

    PubMed  CAS  Google Scholar 

  42. Drake L., Dinehart S., Farmer E., et al. Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol 1996; 35 (4): 615–9

    Article  PubMed  CAS  Google Scholar 

  43. Isaksson M., Brandao F.M., Bruze M., et al. Recommendation to include budesonide and tixocortol pivalate in the European standard series, ESCD and EECDRG: European Society of Contact Dermatitis. Contact Dermatitis 2000; 43 (1): 41–2

    Article  PubMed  CAS  Google Scholar 

  44. Du Vivier A., Stoughton R.B. Acute tolerance to effects of topical glucocorticosteroids. Br J Dermatol 1976; 94: 25–32

    Article  PubMed  Google Scholar 

  45. Clement M., Phillips H., Du Vivier A. Is steroid tachyphylaxis preventable? Clin Exp Dermatol 1985; 10: 22–9

    Article  PubMed  CAS  Google Scholar 

  46. Franz T.J., Parsell D.A., Halualani R.M., et al. Betamethasone valerate foam 0.12 %: a novel vehicle with enhanced delivery and efficacy. Int J Dermatol 1999; 38: 628–32

    Article  PubMed  CAS  Google Scholar 

  47. Schmid M.H., Korting H.C. Liposomes: a drug carrier system for topical treatment in dermatology. Crit Rev Ther Drug Carrier Syst 1994; 11 (2–3): 97–118

    PubMed  CAS  Google Scholar 

  48. Giannotti B., Pimpinelli N. Topical corticosteroids: which drug and when? Drugs 1992; 44 (1): 65–71

    Article  PubMed  CAS  Google Scholar 

  49. Long C.C., Mills C.M., Finlay A.Y. A practical guide to topical therapy in children. Br J Dermatol 1998; 138: 293–6

    Article  PubMed  CAS  Google Scholar 

  50. Lagos B.R., Maibach A.I. Frequency of application of topical corticosteroids: an overview. Br J Dermatol 1998; 139: 763–6

    Article  PubMed  CAS  Google Scholar 

  51. Paul M.A., Krowchuk D.P., Hitchcock M.G., et al. Lymphomatoid papulosis: successful weekly pulse superpotent topical corticosteroid therapy in three pediatric patients. Pediatr Dermatol 1996; 13 (6): 501–6

    Article  PubMed  CAS  Google Scholar 

  52. Van der Vleuten C.J., Van Vlijmen I.M., De Jong E.M., et al. Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17 propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res 1999; 291 (7–8): 390–5

    Article  PubMed  Google Scholar 

  53. Mori M., Pimpinelli N., Giannotti B. Topical corticosteroids and unwanted local effects: improving the benefit/risk ratio. Drug Saf 1994; 10 (5): 406–12

    Article  PubMed  CAS  Google Scholar 

  54. Spencer C.M., Wiseman L.R. Topical fluticasone propionate: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. BioDrugs 1997; 7 (4): 318–34

    Article  PubMed  CAS  Google Scholar 

  55. Quintiliani R. Hypersensitivity and adverse reactions associated with the use of newer intranasal corticosteroids for allergic rhinitis. Curr Ther Res Clin Exp 1996; 57: 478–88

    Article  CAS  Google Scholar 

  56. Wilkinson S.M., Beck M.H. Fluticasone propionate and mometasone furoate have a low risk of contact sensitisation. Contact Dermatitis 1996; 34: 365–6

    Article  PubMed  CAS  Google Scholar 

  57. Corazza M., Virgili A. Allergic contact dermatitis from a-methylprednisolone aceponate and budesonide. Contact Dermatitis 1998; 38: 356–7

    Article  PubMed  CAS  Google Scholar 

  58. Goh C.L., Lim J.T., Leow Y.H., et al. The therapeutic efficacy of mometasone furoate cream 0.1 % applied once daily vs clobetasol propionate cream 0.05 % applied twice daily in chronic eczema. Singapore Med J 1999; 40 (5): 341–4

    PubMed  CAS  Google Scholar 

  59. Kelly J.W., Cains G.D., Rallings M., et al. Safety and efficacy of mometasone furoate cream in the treatment of steroid responsive dermatoses. Aust J Dermatol 1991; 32 (2): 85–91

    Article  CAS  Google Scholar 

  60. Vernon H.J., Lane A.T., Weston W. Comparison of mometasone furoate 0.1 % cream and hydrocortisone 1.0 % cream in the treatment of childhood atopic dermatitis. J Am Acad Dermatol 1991; 24 (4): 603–7

    Article  PubMed  CAS  Google Scholar 

  61. Haapasaari K.M., Resteli J., Karvonen J., et al. Effect of hydrocortisone, methylprednisolone aceponate and mometasone furoate on collage synthesis in human skin in vivo. Skin Pharmacol 1997; 10 (5–6): 261–4

    Article  PubMed  CAS  Google Scholar 

  62. Prakash A., Benfield P. Topical mometasone: a review of its pharmacological properties and therapeutic use in the treatment of dermatological disorders. Drugs 1998; 55 (1): 145–63

    Article  PubMed  CAS  Google Scholar 

  63. Lange K., Kleuser B., Gysler A., et al. Cutaneous inflammation and proliferation in vitro: differential effects and mode of action of topical glucocorticosteroids. Skin Pharmacol Appl Skin Physiol 2000; 13 (2): 93–103

    Article  PubMed  CAS  Google Scholar 

  64. Lange K., Gysler A., Bader M., et al. Prednicarbate versus conventional topical glucocorticosteroids: pharmacodynamic characterization in vitro. Pharm Res 1997; 14 (12): 1744–9

    Article  PubMed  CAS  Google Scholar 

  65. Kecskés A., Jahn P., Matthes H., et al. Systemic effects of topically applied methylprednisolone aceponate in healthy volunteers. J Am Acad Dermatol 1993; 28 (5): 789–92

    Article  PubMed  Google Scholar 

  66. Kecskés A., Jahn P., Lange L. Local tolerability of topically applied methylprednisolone aceponate. J Am Acad Dermatol 1993; 28 (5): 786–8

    Article  PubMed  Google Scholar 

  67. Günther C., Kecskes A., Staks T., et al. Percutaneous absorption of methylprednisolone aceponate following topical application of Advantan® lotion on intact, inflamed and stripped skin of male volunteers. Skin Pharmacol Appl Skin Physiol 1998; 11: 35–42

    Article  PubMed  Google Scholar 

  68. Hoffmann K., Auer T., Stucker M., et al. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone. J Eur Acad Dermatol Venereol 1998; 10 (2): 137–42

    Article  PubMed  CAS  Google Scholar 

  69. Kecskés A., Heger-Mahn D., Kuhlmann R.K., et al. Comparison of the local and systemic side effects of methylprednisolone aceponate and mometasone furoate applied as ointments with equal anti-inflammatory activity. J Am Acad Dermatol 1993; 29 (4): 576–80

    Article  PubMed  Google Scholar 

  70. Balato N., Patruno C., Lembo G., et al. Contact sensitisation to 6 alpha-methylprednisolone aceponate. Am J Contact Dermat 1997; 8 (1): 24–5

    Article  PubMed  CAS  Google Scholar 

  71. Meingassner J.G., Grassberger M., Fahrngruber H., et al. A novel anti-inflammatory drug, Pimecrolimus (SDZ-ASM-981), for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 1997; 137: 568–76

    Article  PubMed  CAS  Google Scholar 

  72. Van Leent E.J.M., Gräber M., Thurston M., et al. Effectiveness of the ascomycin macrolatum SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998; 134: 805–9

    Article  PubMed  Google Scholar 

  73. Grassberger M., Baumruker T., Hiestand P., et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 1999; 141: 264–73

    Article  PubMed  CAS  Google Scholar 

  74. Neckermann G., Bavandi A., Meingassner J.G. Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 2000; 142: 669–79

    Article  PubMed  CAS  Google Scholar 

  75. Ruzicka T., Assmann T., Homey B. Tacrolimus: the drug of the turn of the millennium? Arch Dermatol 1999; 135: 574–80

    Article  PubMed  CAS  Google Scholar 

  76. Assmann T., Homey B., Ruzicka T. Applications of tacrolimus for the treatment of skin disorders. Immunopharmacology 2000; 47 (2–3): 203–13

    Article  PubMed  CAS  Google Scholar 

  77. Leung D.Y.M., Soter N.A. Cellular and immunologic mechanisms in atopic dermatitis. J Am Acad Dermatol 2001; 44 Suppl. 1: S1–12

    Article  PubMed  CAS  Google Scholar 

  78. Bekersky I., Fitzsimmons W., Tanase A., et al. Nonclinical and early clinical development of tacrolimus ointment for the treatment of atopic dermatitis. J Am Acad Dermatol 2001; 44 Suppl. 1: S17–27

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, University of Florence, Via degli Alfani 37, 50121-, Florence, Italy

    Benedetta Brazzini &  Nicola Pimpinelli

Authors
  1. Benedetta Brazzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nicola Pimpinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicola Pimpinelli.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brazzini, B., Pimpinelli, N. New and Established Topical Corticosteroids in Dermatology. Am J Clin Dermatol 3, 47–58 (2002). https://doi.org/10.2165/00128071-200203010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128071-200203010-00005

Keywords

Search

Navigation